Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine

MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed patient enrollment in the efficacy portion of its initial Phase 3 clinical trial evaluating MAP0004, the company's novel, orally inhaled product candidate for the acute treatment of migraine.

"In our Phase 2 clinical trial, MAP0004 demonstrated the potential to be both fast acting and long-lasting, providing pain relief in as fast as ten minutes with relief lasting for 24 and 48 hours, so we believe that MAP0004 has the potential to be a first-line therapy for migraine patients. We would like to thank our investigators as well as their patients for their strong interest and support for studying the potential benefits of MAP0004," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "We look forward to announcing clinical data from the efficacy portion of the trial in the first half of this year."

The Phase 3 multi-center, randomized, double-blind, placebo-controlled trial in approximately 850 migraine sufferers is evaluating the safety and efficacy of MAP0004 as a potential acute treatment for migraine. The primary efficacy endpoints are pain relief and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. The study is also evaluating earliest onset of pain relief, pain relief at 10 minutes, and sustained pain relief and freedom at 24 and 48 hours. Patients enrolled in the trial are being evaluated for the treatment of a single migraine and may continue in a long-term safety arm of the trial, enrollment in which is ongoing. MAP Pharmaceuticals is conducting this first Phase 3 trial pursuant to a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration.

MAP0004 is a novel, orally inhaled acute migraine medication in development which has a multi-targeted mechanism of action, utilizes the company's proprietary TEMPO(R) inhaler and is designed to optimize the key characteristics of dihydroergotamine, an active ingredient which has been used to effectively and safely treat migraines for over 60 years. MAP0004 has the potential to provide a faster onset of action than currently available migraine treatments, with sustained pain relief and pain freedom, in an easy-to-use, non-invasive, at-home therapy. In a Phase 2 clinical trial, patients reported pain relief in as fast as 10 minutes, with sustained relief to 24 and 48 hours. The safety data generated to date have shown MAP0004 to be well tolerated with no significant adverse events reported.

Migraine is a common, debilitating neurological disease affecting approximately 30 million people in the United States, according to the National Headache Foundation (NHF). Common symptoms include recurrent attacks of headaches, nausea, vomiting and sensitivity to light and sound. According to the NHF, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the development, therapeutic potential, and potential safety and efficacy of MAP Pharmaceuticals' MAP0004 product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the enrollment, conduct, completion and reporting of clinical trials, as well as risks relating to failure to achieve favorable clinical outcomes, and that MAP0004 will not be approved for commercial use by the United States Food and Drug Administration. The reader is cautioned not to unduly rely on the forward- looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2008, and available at

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
(Date:10/27/2015)... , Oct. 27, 2015 In the ... issues of concern for various industry verticals such as ... due to the growing demand for secure & simplified ... various ,sectors, such as hacking of bank accounts, misuse ... electronic equipment such as PC,s, laptops, and smartphones are ...
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
Breaking Biology News(10 mins):